| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Today’s Big NewsNov 25, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now. 
|
|
| By Kevin Dunleavy After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue increases among the top companies in the biopharma industry, there was a new growth champion in the third quarter. With a 32% revenue increase, Pfizer jumped into the top spot. |
|
|
|
By Nick Paul Taylor Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the plug on another phase 3 trial and an open-label extension. |
By Kevin Dunleavy Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification update. |
By Zoey Becker In the phase 3 inMIND study, Monjuvi—added to Bristol Myers Squibb's Revlimid and Roche's Rituxan—triggered a 57% reduction in the risk of disease progression, relapse or death in R/R FL patients compared with those who were treated with placebo, Revlimid and Rituxan. |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now! 
|
|
By Nick Paul Taylor A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy has missed its primary endpoint. The biotech plans to talk to the FDA about the next steps in SMA and is stepping up its interest in obesity on the strength of the data. |
By Fraiser Kansteiner President-elect Donald Trump has named Johns Hopkins surgeon and author Martin Makary, M.D., as his choice for FDA commissioner during his upcoming term. |
By Gabrielle Masson Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate candidates into the clinic. |
By Kevin Dunleavy The FDA has signed off on BridgeBio's Attruby (acoramidis), a potential blockbuster to treat patients with the rare heart disease transthyretin amyloid cardiomyopathy. With the nod, BridgeBio will challenge Pfizer’s powerhouse Vyndaqel franchise, which dominates the indication. |
By Andrea Park RFK Jr. has previously expressed a desire to put a stop to DTC pharma ads in the U.S.—which is one of only two countries in the world, along with New Zealand, where prescription drugs can be directly advertised to consumers. |
By Conor Hale Intera Oncology’s approach—approved by the FDA more than two decades ago—includes an implantable drug reservoir connected to the hepatic artery. |
By Darren Incorvaia In order to more quickly recruit volunteers into clinical trials, a team of researchers at the NIH has turned to artificial intelligence. The scientists built a large language model, TrialGPT, that can scan medical summaries of patients and match them to clinical trials they are eligible for. |
By Joseph Keenan Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due to the presence of an active pharmaceutical ingredient (API) that came from an unapproved vendor. |
By Gabrielle Masson Klothea will conduct R&D work related to Advantage’s portfolio based around Klotho, a protein tied to certain anti-aging properties. |
By Conor Hale The new balloon-expanded heart valve is set to complement Abbott’s self-expandable Navitor TAVR implant, the company said, which received an FDA approval for its latest generation in early 2023. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use. 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
